Abstract
An epithermal neutron beam has been developed1,2 for Boron Neutron Capture Therapy (BNCT) at the Massachusetts Institute of Technology Research Reactor (MITR-II). The neutron beam has been used to treat two patients as part of a Phase I clinical trial for subcutaneous melanoma of the extremities. The clinical dosimetry of epithermal neutron beams for BNCT is considerably different from that of fast neutron beams used for fast neutron therapy. In BNCT, the incident radiation field consists primarily of neutrons in the 0.5 eV to ≈20 keV range; higher energy neutrons, with energies up to 15 MeV, and photons of 0–10 MeV, are present as contaminants. Therefore, separate macroscopic doses, including those from thermal and fast neutrons, photons, and the B-10(n,α)Li-7 reaction, need to be determined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
